Browse studies

Find your next paid study

1,369 recruiting studies matching your filters

A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study

This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasiden…

Myelodysplastic Syndrome

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06577441

Observational

PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for can…

Ampulla of Vater CarcinomaAppendix CarcinomaCarcinoma of Unknown Primary With Gastrointestinal Profile+7 more

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT07283939

Observational

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leukemia

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who ac…

B-AllAcute Lymphoblastic Leukemia

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05621291

Phase 1

Individualized Response Assessment to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Primaries

Background: Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS …

Peritoneal MesotheliomaPeritoneal CarcinomatosisOvarian Cancer+4 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04847063

Phase 3

A Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy and Safety of Nerandomilast Over at Least 52 Weeks in Patients With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (FIBRONEER-ACT)

This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they h…

Interstitial Lung Diseases

Estimated

~$10 – $7,500

Boehringer IngelheimNCT07540988

Natural History of Treated Neurocysticercosis and Long-Term Outcomes

Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection …

CysticercosisNeurocysticercosis

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00001205

SnapChole: An International, Time-Bound Prospective Platform Study of Management Strategies and Outcomes in Acute Calculous Cholecystitis

This study aims to understand how different treatment approaches for acute gallbladder inflammation (acute calculous cholecystitis) affect patient outcomes in …

Cholecystitis, Acute

Estimated

~$10 – $1,125

European Society for Trauma and Emergency SurgeryNCT07568080

Phase 2

Phase II Trial of Enfortumab Vedotin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma

The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

Adenoid Cystic Carcinoma

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06891560

Phase 2

NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours

This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with…

Metastatic Digestive System Neuroendocrine Tumor G1Metastatic Digestive System Neuroendocrine Tumor G2Unresectable Digestive System Neuroendocrine Tumor G1+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05773274

Phase 2

Phase 2 Study of Golcadomide With Rituximab as a Bridging Therapy Prior to CAR-T for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)

This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patient…

Large B-Cell Lymphoma With IRF4 RearrangementRecurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent ALK-Positive Large B-Cell Lymphoma+28 more

Phase 1

Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now b…

B-NHLB-Non Hodgkin LymphomaAcute Lymphocytic Leukemia+8 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05442515

Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection

The purpose of this study is to evaluate, treat and follow patients with parasitic infections. People with a known or suspected parasitic infection who are at…

MalariaIntestinal WormsGI Protozoa+2 more

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00001645